Data Sheet 1_Genetic risk for neurodevelopmental disorders as a potential factor affecting

Polygenic risk scores for ADHD and ASD calculated from GWAS data on postmortem brains of 24 schizophrenia patients and 48 controls. The dataset, authored by Kazusa Miyahara and last updated in April 2026, includes correlation analyses with clinical symptom severity and antipsychotic responsiveness scores for 19 patients. Exploratory gene expression and pathway analyses were also performed on prefrontal cortex samples.

Use Cases

• Correlating polygenic risk scores for neurodevelopmental disorders with antipsychotic treatment response based on the described ARS scores.
• Investigating gene expression differences in the prefrontal cortex between schizophrenia patient subgroups based on ADHD-PRS.
• Analyzing pathway enrichment for genes differentially expressed in relation to neurodevelopmental genetic risk.
• Studying the overlap of genomic architecture between schizophrenia, ADHD, and autism spectrum disorder using polygenic risk scores.

Strengths

• Includes polygenic risk scores derived from genome-wide association study (GWAS) data.
• Contains clinical correlation data for 19 schizophrenia patients, linking genetics to symptom severity and treatment response.
• License is CC-BY-4.0, permitting broad reuse with attribution.

Limitations

• Sample size is limited to 24 patients and 48 controls, as stated in the description.
• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.

Provenance

Source

figshare, author Kazusa Miyahara

Collection Method

Data derived from postmortem brain GWAS and publicly available GWAS summary statistics for PRS calculation.

Freshness

Last updated 2026-04-27 05:18:06; freshness should be verified.